Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Kenneth P. Norquay, CMTInex Pharmaceuticals CorpIEX.TOCOMMENTApr 17, 2007

This is a penny stock and they tend to be promoted.
$1.10

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY
A well-run company. Probably one of the lower risk biotech investments in Canada. Their product Onco TCS should be approved this year. Have a good marketing partnership with Enzon.
BUY
If you like biotechs, this could be OK. Speculative.
DON'T BUY
Need to get FDA approval. Too speculative for their funds.
HOLD
Good cash balance. Their problemsare delays in getting their product to market. Needs a good partner.
BUY
Needs approval by FDA. Nice cash balance.
DON'T BUY
There will be some delay in their filings with FDA.
WEAK BUY
In phase 3 trials. Speculative.
PAST TOP PICK
(Was a top pick on Dec 5 no change) Still likes.
TOP PICK
A speculative choice, but has a good RISK/RETURN.
BUY
Just partnered which is good. Good company